Across TCGA pan-cancer cohorts, GCNT1P2 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of GCNT1P2’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where GCNT1P2 RNA is repressed in tumor relative to normal tissue. In most cancer types GCNT1P2 is over-expressed in tumor, although a few such as BRCA show the opposite, repressed pattern.
BRCA are the cancer types where GCNT1P2 tumor–normal differential expression is most reproducible.